PLA2R1

Across TCGA pan-cancer cohorts, PLA2R1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLA2R1 data layer compared with 27 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLA2R1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLA2R1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where PLA2R1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.279	0.738	.012	7	view →
CCRCC	OS	Median	II,III,IV	0.744	0.865	.024	4	view →
HNSC	OS	Tertile	IV	0.590	0.876	.028	4	view →
UCEC	DFS	Median	II,III,IV	0.386	1.000	.036	4	view →
GBM	DFS	Tertile	All	0.624	0.320	.026	3	view →
LSCC	DFS	Median	All	0.892	1.000	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLA2R1–PDAC (OS)

Open the PDAC breakdown →